These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 25458914)
21. New respiratory virus (chicken pox, influenza and respiratory syncytial virus) vaccines: efficacy, necessity and policy for the tropical world at present. Wiwanitkit V Hum Vaccin; 2009 Sep; 5(9):621-2. PubMed ID: 19363304 [TBL] [Abstract][Full Text] [Related]
22. Engineering a Virus-Like Particle as an Antigenic Platform for a Pfs47-Targeted Malaria Transmission-Blocking Vaccine. Yenkoidiok-Douti L; Williams AE; Canepa GE; Molina-Cruz A; Barillas-Mury C Sci Rep; 2019 Nov; 9(1):16833. PubMed ID: 31727945 [TBL] [Abstract][Full Text] [Related]
23. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus. Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001 [TBL] [Abstract][Full Text] [Related]
24. A Single Intramuscular Dose of a Plant-Made Virus-Like Particle Vaccine Elicits a Balanced Humoral and Cellular Response and Protects Young and Aged Mice from Influenza H1N1 Virus Challenge despite a Modest/Absent Humoral Response. Hodgins B; Yam KK; Winter K; Pillet S; Landry N; Ward BJ Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021303 [TBL] [Abstract][Full Text] [Related]
26. Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge. Gao X; Wang W; Li Y; Zhang S; Duan Y; Xing L; Zhao Z; Zhang P; Li Z; Li R; Wang X; Yang P Antiviral Res; 2013 Apr; 98(1):4-11. PubMed ID: 23416215 [TBL] [Abstract][Full Text] [Related]
27. Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection. Qiao L; Zhang Y; Chai F; Tan Y; Huo C; Pan Z Antiviral Res; 2016 Jul; 131():131-40. PubMed ID: 27154395 [TBL] [Abstract][Full Text] [Related]
28. Analysis of Immune Epitopes of Respiratory Syncytial Virus for Designing of Vectored Vaccines Based on Influenza Virus Platform. Isakova-Sivak IN; Korenkov DA; Fedorova EA; Tretiak TS; Matyushenko VA; Smolonogina TA; Rudenko LG Bull Exp Biol Med; 2016 Aug; 161(4):533-7. PubMed ID: 27590768 [TBL] [Abstract][Full Text] [Related]
29. [The development of influenza virus-like particle vaccines]. Zhang LX; Yu ZJ; Zhou JF; Shu YL Bing Du Xue Bao; 2011 Jul; 27(4):402-8. PubMed ID: 21874913 [No Abstract] [Full Text] [Related]
30. Malaria vaccine based on self-assembling protein nanoparticles. Burkhard P; Lanar DE Expert Rev Vaccines; 2015; 14(12):1525-7. PubMed ID: 26468608 [TBL] [Abstract][Full Text] [Related]
31. Subunit and virus-like particle vaccine approaches for respiratory syncytial virus. Morrison TG; Walsh EE Curr Top Microbiol Immunol; 2013; 372():285-306. PubMed ID: 24362695 [TBL] [Abstract][Full Text] [Related]
32. A novel H6N1 virus-like particle vaccine induces long-lasting cross-clade antibody immunity against human and avian H6N1 viruses. Yang JR; Chen CY; Kuo CY; Cheng CY; Lee MS; Cheng MC; Yang YC; Wu CY; Wu HS; Liu MT; Hsiao PW Antiviral Res; 2016 Feb; 126():8-17. PubMed ID: 26593980 [TBL] [Abstract][Full Text] [Related]
33. Identification of an Immunogenic Mimic of a Conserved Epitope on the Plasmodium falciparum Blood Stage Antigen AMA1 Using Virus-Like Particle (VLP) Peptide Display. Crossey E; Frietze K; Narum DL; Peabody DS; Chackerian B PLoS One; 2015; 10(7):e0132560. PubMed ID: 26147502 [TBL] [Abstract][Full Text] [Related]
34. Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses. Khan F; Porter M; Schwenk R; DeBot M; Saudan P; Dutta S PLoS One; 2015; 10(11):e0142035. PubMed ID: 26571021 [TBL] [Abstract][Full Text] [Related]
35. Epidermal delivery of protein and DNA vaccines. Dean HJ Expert Opin Drug Deliv; 2005 Mar; 2(2):227-36. PubMed ID: 16296750 [TBL] [Abstract][Full Text] [Related]
36. Protection against multiple subtypes of influenza viruses by virus-like particle vaccines based on a hemagglutinin conserved epitope. Chen S; Zheng D; Li C; Zhang W; Xu W; Liu X; Fang F; Chen Z Biomed Res Int; 2015; 2015():901817. PubMed ID: 25767809 [TBL] [Abstract][Full Text] [Related]
37. A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk. Yang JR; Cheng CY; Chen CY; Lin CH; Kuo CY; Huang HY; Wu FT; Yang YC; Wu CY; Liu MT; Hsiao PW Antiviral Res; 2017 Apr; 140():62-75. PubMed ID: 28093338 [TBL] [Abstract][Full Text] [Related]
38. Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro. Hendin HE; Pillet S; Lara AN; Wu CY; Charland N; Landry N; Ward BJ Vaccine; 2017 May; 35(19):2592-2599. PubMed ID: 28389100 [TBL] [Abstract][Full Text] [Related]
39. A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles. Ramirez A; Morris S; Maucourant S; D'Ascanio I; Crescente V; Lu IN; Farinelle S; Muller CP; Whelan M; Rosenberg W Vaccine; 2018 Feb; 36(6):873-880. PubMed ID: 29306508 [TBL] [Abstract][Full Text] [Related]
40. Protection conferred by virus-like particle vaccines against respiratory syncytial virus infection in mice by intranasal vaccination. Gu H; Li T; Han L; Zhu P; Zhang P; Zhang S; Sun S; Duan Y; Xing L; Zhao Z; Lai C; Wen B; Wang X; Yang P Hum Vaccin Immunother; 2015; 11(4):1057-64. PubMed ID: 25933187 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]